Teft et al., 2017)
Jingye Zhou, Eccogene CEO Eccogene files for Hong Kong IPO to back development of GLP-1 pipeline Eccogene, a clinical-stage biotech whose oral GLP-1 drug forms the backbone of AstraZenecas obesity pipeline, is planning an initial public offering on the Hong Kong Sign up to read this article for free
The lack of transparency is what they have a massive problem with
Apple peel polyphenols and their beneficial actions on oxidative stress and inflammation
Reduced levels of the mitochondrial autophagy-associated protein Parkin in the substantia nigra may contribute to the development of Parkinsons disease (PD) in db/db mice and high-fat diet-induced diabetic mice.41 As discussed above, mitochondrial dysfunction (mitochondrial bioenergetics, calcium buffering) and mitochondrial quality control systems (mitochondrial dynamics, mitophagy, mitochondrial biogenesis) may be involved in the pathological mechanisms of diabetes-related NDs
Collectively, these data suggest that chronic treatment with a GLP-1R G-protein-biased agonist peptide maintains eWAT mass by increasing adipogenesis and prevents ectopic fat deposition in the liver induced by high-fat diet
.jpg)
